NOTCH3 and hepatocellular carcinoma: The selective targeting of Notch3 should be preferred for HCC therapy to avoid additional unknown effects to non-neoplastic cirrhotic liver cells that stain negative for Notch3 and positive for others Notch receptors such as Notch4 [69].